Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
Bushra Salman: Avatrombopag Shows Promise in Heavily Pretreated Chronic ITP
Bushra Salman/LinkedIn
Jul 31, 2026, 10:08

Bushra Salman: Avatrombopag Shows Promise in Heavily Pretreated Chronic ITP

Bushra Salman, Pharmacist at Sultan Qaboos University, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Frontiers in Medicine, adding:

“I am delighted to share our latest publication in Frontiers in Medicine:

‘Avatrombopag in Heavily Pretreated Chronic Immune Thrombocytopenia: A Single-Center Experience from Oman.’

Patients with chronic immune thrombocytopenia (ITP) who have failed multiple prior therapies remain challenging to treat.

In our real-world case series from Oman, avatrombopag demonstrated clinically meaningful benefits beyond improving platelet counts.

Key findings include:

  • 75 percent of patients achieved platelet counts greater than or equal to 50 × 10⁹/L.
  • 60 percent of patients with high baseline platelet transfusion requirements experienced a reduction in platelet transfusion burden.
  • 83.3 percent achieved a steroid-sparing effect, with 66.7 percent becoming completely steroid-free during follow-up.

These findings highlight the potential of avatrombopag not only to improve platelet responses but also outcomes that can significantly improve patient care and quality of life.”

Title: Avatrombopag in heavily pretreated chronic immune thrombocytopenia: a single center experience from Oman

Authors: Nashwa Al-Sharji, Bushra Salman, Shireen Al-Zadjali, Mohammed Al-Huneini

Bushra Salman: Avatrombopag Shows Promise in Heavily Pretreated Chronic ITP

Stay updated on all scientific advances with Hemostasis Today.
 

Avatrombopag Bushra Salman Chronic ITP Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine Mohammed Al-Huneini Nashwa Al-Sharji Shireen Al-Zadjali
NewsFeed